We are a translational medicine company focused on bringing innovative science to market. We are developing a monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte macrophagecolony stimulating factor (GM-CSF).
IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress.
IZN-101 is also in development for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), a debilitating arthritic disease with no cure. IZN-101 has demonstrated its efficacy in a Phase IIb study in RA (NEXUS) and is a potential novel treatment, with a novel mode of action.
Investors and Collaborators
Izana Bioscience has partners who share our commitment to developing IZN-101 for the benefit of patients
Izana Bioscience is led by an experienced management team and supported by a world class clinical advisory board
Send us an email using the form and one of the team will be in touch with you soon.